Innovators Façade Systems Limited

Industrials — Engineering & Construction · BSE

₹112.85+₹2.85 (+2.59%)

DalalBaazaar Score

63 / 100

🟢 Good

Verdict

REASONABLE

Risk

Low

Driven by micro-cap size, which brings thin liquidity.

In simple words: Reasonable but unspectacular business quality, with modest growth. Nothing on this snapshot stands out as an immediate concern — the usual checks on business quality and management still apply.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:49 pm

Understanding the Business

Company site ↗

The 60-second version of Innovators Façade Systems Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Innovators Façade Systems Limited engages in the designing, engineering, fabrication, supply, and installation of facade systems in India.

IndustryEngineering & Construction

SectorIndustrials

Employees401

Annual revenue₹227 Cr

How does it make money?

Turns over ₹227 Cr a year. Of every ₹100 of sales, about ₹6 reaches shareholders as profit, with ₹13 left at the operating level before interest, tax and depreciation. Each of its 401 employees supports ₹56.6 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹56.6 lakh

Who are its competitors?

The closest listed comparisons in its industry are LARSEN & TOUBRO LTD., ADANI PORT & SEZ LTD, SIEMENS LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of 12.8% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE14.1%

What has been driving growth?

Sales and margins have both contributed to where profit is now. Over 3 years revenue moved +26% while net margin moved +28% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+26%

Margin effect+28%

DalalBaazaar Score

63/ 100

Good

Weighted across six categories. Every point is explained below.

✗ ROE of 8.1% is weak

Quality vs. Valuation

Company Quality

62/ 100

Average

How good the business is, ignoring the share price entirely.

Valuation

84/ 100

Cheap

What you are being asked to pay, ignoring how good the business is.

A reasonable business at a reasonable price — neither the quality nor the valuation stands out in either direction.

Historical Valuation

Current P/E

15.7x

3Y Median

25.3x

40 monthly readings · mean 29.0x · range 12.5x–54.7x

Sector Median

30.1x

median of 3 sector peers

🟢Current valuation is approximately 38% below its 3y median of 25.3x. Cheaper than its own history, which is worth a reason too: the market may be pricing in something the backward-looking numbers do not show.

🟢Against its sector it trades 48% below the peer median of 30.1x.

vs. its own history

Cheap

25.3x median over 40 months · -38%

vs. sector peers

Cheap

30.1x median of 3 peers · -48%

vs. generic bands

Fair

15x–35x

EV/EBITDA

7.5x

PEG

0.91

What's Good / What's Bad

🟢 What's Going Well5

Margins are improving
EBITDA margin is up from 9.2% to 12.8% over 3 years.
Cash generation is improving
Free cash flow is up 313% over 3 years.
Return on capital is rising
ROCE has improved from 8.9% to 12.8%.
Very low debt
Debt/Equity of 0.26x leaves the balance sheet with plenty of headroom.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

No automated checks triggered

None of the automated financial checks below were triggered on the years of data available. That is not the same as a clean bill of health — see what could not be checked.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Margin expansion has further to run
EBITDA margin has risen from 9.2% to 12.8%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Priced below its own history
The stock trades 38% below its own median multiple. If the business performs as it has and simply re-rates back to normal, that gap is return on its own.
Cheaper than its peers
It trades 48% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Self-funding with balance-sheet headroom
Positive free cash flow of ₹30 Cr alongside low debt means growth, buybacks or dividends need no outside money — and a downturn can be absorbed rather than refinanced.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Growth barely outpaces inflation
Revenue compounding at 7.9% a year is close to the rate prices rise, so the business is gaining little ground in real terms. That leaves the share price dependent on a re-rating rather than on earnings growth.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 11%✓ 12.8%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Revenue growth stays above 6% a year✓ 7.9% CAGR
Latest reported year was 34.1%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
3Free cash flow remains positive✓ ₹30 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 1.6x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 10%✓ 12.8%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

7 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

5 good · 6 neutral · 0 weak

Market Cap

₹213 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

15.7x

Fair

Fairly valued against the generic band

P/B Ratio

1.22x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹7.19

Profitable

Profitable on a per-share basis

ROE

8.1%

Moderate

Moderate capital efficiency

ROCE

12.8%

Moderate

Moderate return on the capital in the business

Debt/Equity

0.26x

Low

Conservative leverage

Revenue Growth (YoY)

34.1%

Healthy

Healthy top-line growth

Profit Growth (YoY)

8.4%

Modest

Slow profit growth

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹30 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

ROA

4.6%

Average

Average asset productivity

Operating Margin

9.2%

Average

Average margins

Net Margin

6.0%

Average

Average bottom-line conversion

Current Ratio

1.35

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.65

Defensive

Steadier than the market

52W Range Position

Near low

Near its 52-week low

Technical Snapshot

SMA 20 / SMA 50

114.0 / 115.4

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

47.5

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹181 Cr	₹215 Cr	₹220 Cr	₹227 Cr	+7.9%
EBITDA	₹17 Cr	₹28 Cr	₹33 Cr	₹29 Cr	+20.4%
EBITDA Margin	9.2%	12.8%	14.8%	12.8%	—
PAT (Net Profit)	₹8 Cr	₹15 Cr	₹16 Cr	₹14 Cr	+17.2%
EPS	₹4.46	₹8.09	₹8.49	—	—
ROE	6.5%	10.5%	9.9%	7.7%	—
ROCE	8.9%	15.8%	16.0%	12.8%	—
Total Debt	₹39 Cr	₹43 Cr	₹61 Cr	₹45 Cr	+5.4%
Free Cash Flow	₹7 Cr	₹8 Cr	-₹3 Cr	₹30 Cr	+60.4%

🟢 Revenue has grown at 7.9% a year over 3 years.

🟢 EBITDA has grown at 20.4% a year over 3 years.

🟢 EBITDA Margin has risen from 9.2% to 12.8% over 3 years (+3.6 pts).

🟢 PAT (Net Profit) has grown at 17.2% a year over 3 years.

🟢 ROE has risen from 6.5% to 7.7% over 3 years (+1.3 pts).

🟢 ROCE has risen from 8.9% to 12.8% over 3 years (+3.9 pts).

🔴 Total Debt has grown at 5.4% a year over 3 years.

🟢 Free Cash Flow has grown at 60.4% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹359 Cr

Total Liabilities

₹184 Cr

Cash & Equivalents

₹41 Cr

Operating Cash Flow

₹38 Cr

Capex

-₹8 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

77.3%

Peer Comparison

Company	P/E	ROE
LARSEN & TOUBRO LTD.	30.1x	15.2%
ADANI PORT & SEZ LTD	29.9x	14.1%
SIEMENS LTD	88.8x	10.5%

Recent News

2 positive2 mixed2 general

Vijay Kedia sells 4 lakh shares of this microcap facade maker in Q1, stock down 35% in 6 months. Do you ow

The Economic Times, 28 JulResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Innovators Facade Systems Share Price rises 8.94% today

Univest, 17 SeptPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Innovators Façade Systems FY26 revenue rises, order book hits record high

scanx.trade, 30 MayOrder win

🟢Potentially positiveOrder wins add to future revenue, though the effect depends on the contract's size against annual sales and on when it is executed.

Reliance Order Win Lifts Innovators; Shares Up 0.76%

HDFC Sky, 05 MayOrder win

🟢Potentially positiveOrder wins add to future revenue, though the effect depends on the contract's size against annual sales and on when it is executed.

Innovators Facade Systems schedules 27th AGM for September 22

scanx.trade, 25 Aug

Innovators Facade Systems share price zooms 11% on winning ₹76.82 Cr order from Lodha Developers

Alice Blue, 28 Apr

Watch Items

Trading very close to its 52-week low — worth checking whether this reflects a temporary setback or a structural problem.
Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

StrongFinancial Health · Growth · Valuation

MiddlingBusiness Quality · Risk

WeakProfitability

Points for each in the Score ↑

Unremarkable in both directions

A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you.

All 5 tripwires holding · see Key things to watch ↑